ArticleOpen Access http://dx.doi.org/10.26855/ijcemr.2026.03.005
Analysis of Changes in PINK1 in Patients with Diabetic Nephropathy and Its Relationship with Serum Factors and Clinical Indexes
Dongmei Xu*, Zhihong Zeng, Beibei Wang, Dongyuan Tang, Jiexi Hu
Department of Endocrinology, Longquan People's Hospital, Longquan 323700, Zhejiang, China.
*Corresponding author: Dongmei Xu
This paper is supported by the Lishui Municipal Science and Technology Program (Project No.: 2023SJZC083).
Published: March 3,2026
Abstract
Objective: To investigate the changes in the protein kinase PINK1 in patients with diabetic nephropathy (DN) and to analyze its relationship with serum factors and clinical Indicators. Methods: A total of 90 patients with DN treated between November 2023 and February 2025 were enrolled and randomly divided into three groups according to different treatment regimens, with 30 patients in each group. Patients receiving telmisartan alone were assigned to control group 1; those treated with metformin hydrochloride alone were assigned to control group 2; and patients in the observation group received combined treatment with metformin hydrochloride and telmisartan. Levels of PINK1, reactive oxygen species (ROS), renal function, and serum factors were compared among the three groups. Pearson correlation analysis was used to evaluate the relationships between PINK1 levels, serum creatinine, UACR, and serum factors in DN patients. Results: After intervention, levels of ROS, serum creatinine, UACR, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were decreased, while PINK1 and interleukin-2 (IL-2) levels were increased in all three groups. The observation group showed significantly higher PINK1 mRNA and IL-2 levels compared with control group 1 and control group 2 (P < 0.05), while levels of ROS, IL-6, and TNF-α were significantly lower (P < 0.05). Pearson correlation analysis demonstrated that PINK1 levels were positively correlated with IL-2 (P < 0.05) and negatively correlated with IL-6 and TNF-α (P < 0.05). Conclusion: Combined treatment with metformin hydrochloride and telmisartan in DN patients can increase PINK1 and IL-2 levels and reduce ROS, serum creatinine, UACR, IL-6, and TNF-α levels. PINK1 is significantly correlated with serum factors and clinical Indicators, which may provide guidance for clinical diagnosis and treatment.
Keywords
PINK1; diabetic nephropathy; correlation analysis; metformin hydrochloride; telmisartan
References
[1] Wei R, Peng L, Liang F, et al. Expression of PINK1/Parkin mRNA and its diagnostic value in patients with diabetic nephropathy complicated by upper urinary tract infection. Chin J Nosocomiol. 2023;33(20):3061-3065.
[2] Guo K, Li Y, Xuan C, et al. Yiqi Yangyin Huazhuo Tongluo formula alleviates podocyte injury in diabetic nephropathy mice by regulating miR-21a-5p/FoxO1/PINK1-mediated mitophagy. J South Med Univ. 2025;45(1):27-34.
[3] Liu C, Zhang J, Wang S, et al. Research progress on the protective effects of astragaloside IV on diabetic nephropathy based on podocyte protection. Chin Med Inf. 2024;41(7):61-67.
[4] Tong X, Jia W, Wang X, et al. Guidelines for the integrated traditional Chinese and western medicine diagnosis and treatment of type 2 diabetes mellitus. Jilin J Tradit Chin Med. 2024;44(10):1117-1127.
[5] Chinese Society of Endocrinology, Chinese Alliance for Specialized Treatment of Endocrine and Metabolic Diseases. Chinese consensus on the clinical management of diabetes mellitus complicated with chronic kidney disease. Chin J Endocrinol Metab. 2024;40(6):455-461.
[6] Sun L, Li L. “Renal triad”: treatment strategies for type 2 diabetes mellitus complicated with chronic kidney disease. Chin Med J. 2025;105(12):867-871.
[7] Zhang L, Wang G, Qiu Y, et al. Clinical observation of modified Qingxin Lianzi decoction in the treatment of diabetic nephropathy stage III–IV with qi and yin deficiency syndrome. Chin J Integr Tradit West Nephrol. 2024;25(9):778-782.
[8] Wang H, Han M, Dong S, et al. A systematic review and meta-analysis of randomized controlled trials on the treatment of diabetic nephropathy with the chinese patent medicine shenshuaining. Chin J Integr Tradit West Nephrol. 2023;24(3):238-245.
How to cite this paper
Analysis of Changes in PINK1 in Patients with Diabetic Nephropathy and Its Relationship with Serum Factors and Clinical Indexes
How to cite this paper: Dongmei Xu, Zhihong Zeng, Beibei Wang, Dongyuan Tang, Jiexi Hu. (2026) Analysis of Changes in PINK1 in Patients with Diabetic Nephropathy and Its Relationship with Serum Factors and Clinical Indexes. International Journal of Clinical and Experimental Medicine Research, 10(2), 91-95.
DOI: http://dx.doi.org/10.26855/ijcemr.2026.03.005